ZENBEXUS

This brand name is authorized in United States.

Active ingredients

The drug ZENBEXUS contains one active pharmaceutical ingredient (API):

`1`	Iberdomide UNII `8V66F27X44` - IBERDOMIDE
	Iberdomide is a cereblon-modulating protein degrader that binds to cereblon, a substrate recognition component of an E3 ubiquitin ligase complex. Iberdomide engages cereblon and facilitates recruitment, ubiquitination, and proteasomal degradation of the transcription factors, Aiolos and Ikaros, resulting in anti‑tumor and immunomodulatory activity. In vitro and in vivo, iberdomide treatment showed anti-tumor activity in multiple myeloma (MM) cells and xenografts including in lenalidomide- and pomalidomide-resistant MM cell lines.
	Read more about Iberdomide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZENBEXUS Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	0003-5700, 0003-5710

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.